Progress towards personalized medicine

Drug Discovery Today

Volumn 15, Issue 3-4, 2010, Pages 115-120

  Bates, Stewart ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; GEFITINIB; IMATINIB; MARAVIROC; PANITUMUMAB; SELENTRY; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

BREAST CANCER; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOSE CALCULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; GENE EXPRESSION PROFILING; GOOD CLINICAL PRACTICE; HUMAN; LUNG NON SMALL CELL CANCER; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROGNOSIS;

EID: 75149194970     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.11.001     Document Type: Review

References (51)

1. President's Council of Advisors on Science Technology. Priorities for Personalised Medicine (2008). http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf (http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf)
2. Genomics and Personalized Medicine Act of 2006 (2006) (http://www.govtrack.us/congress/billtext.xpd?bill=s109-3822)
3. Genomics and Personalized Medicine Act of 2008 (2008) (http://www.govtrack.us/congress/bill.xpd?bill=h110-6498)
4. HHS Secretary's Advisory Committee on Genetics Health Society (SACGHS) Report. Personalized Health Care: Pioneers, Partnerships Progress (2008). http://www.hhs.gov/myhealthcare/news/phc_2008_report.pdf (http://www.hhs.gov/myhealthcare/news/phc_2008_report.pdf)
5. US Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (2004). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf (http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf)
6. The Personalized Medicine Coalition. The Case For Personalized Medicine (2009). http://www.ageofpersonalizedmedicine.org/objects/pdfs/thecase.pdf (http://www.ageofpersonalizedmedicine.org/objects/pdfs/thecase.pdf)
7. Langreth R., et al. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 4 (1999) 426-427
8. Jorgensen J.T. New era of personalized medicine: a 10-year anniversary. Oncologist 14 (2009) 557-558
9. Jorgensen J.T. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. Expert Rev. Mol. Diagn. 8 (2008) 689-695
10. Trusheim M.R., et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6 (2007) 287-293
11. Spear B.B., et al. Clinical application of pharmacogenetics. Trends Mol. Med. 7 (2001) 201-204
12. Ross J.S., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14 (2009) 320-368
13. Bang Y., et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J. Clin. Oncol. (2009) 27 abstract 4556
14. Van Custem, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. (2009) 27 abstract 2409
15. Joske D.J. Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med. J. Aust. 189 (2008) 277-282
16. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 112 (2008) 4808-4817
17. National Comprehensive Cancer Network. Clinical Practise Guidelines in Oncology Chronic Myelogenous Leukemia (2009). http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf (http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf)
18. Dowsett M., et al. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 14 (2008) 8019-8026
19. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
20. Harris L., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25 (2007) 5287-5312
21. National Comprehensive Cancer Network. Clinical Practise Guidelines in Oncology Breast Cancer (2009). http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf (http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf)
22. Ross J.S., et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13 (2008) 477-493
23. Bridgewater J., et al. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br. J. Cancer 98 (2008) 1425-1430
24. Monzon F.A., et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J. Clin. Oncol. 27 (2009) 2503-2508
25. Rosenfeld N., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 26 (2008) 462-469
26. US Food and Drug Administration. Draft Guidance for Industry, Clinical Laboratories and FDA Staff: In Vitro Diagnostic Multivariate Index Assays (2007). http://www.fda.gov/cdrh/oivd/guidance/1610.pdf (http://www.fda.gov/cdrh/oivd/guidance/1610.pdf)
27. New Labeling and Distribution Program for Gefitinib (Iressa) (2005) (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm163112.htm)
28. Tamura K., et al. Gefitinib in non-small cell lung cancer. Expert Opin. Pharmacother. 6 (2005) 985-993
29. Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
30. Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
31. Hida T., et al. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev. Anticancer Ther. 9 (2009) 17-35
32. Committee for Medicinal Products for Human Use. Summary of Positive Opinion for Iressa (2009). http://www.emea.europa.eu/pdfs/human/opinion/Iressa_20075609en.pdf (http://www.emea.europa.eu/pdfs/human/opinion/Iressa_20075609en.pdf)
33. Mack G.S. FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 27 (2009) 110-112
34. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 1626-1634
35. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66 (2006) 3992-3995
36. US Food and Drug Administration. Drug-Diagnostic Co-Development Concept Paper (2005). http://www.fda.gov/Cder/genomics/pharmacoconceptfn.pdf April (http://www.fda.gov/Cder/genomics/pharmacoconceptfn.pdf)
37. Hayden E.C. Personalized cancer therapy gets closer. Nature 458 (2009) 131-132
38. US Food and Drug Administration. Table of Valid Biomarkers in the Context of Approved Drug Labels (2009). http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm (http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm)
39. Emmelkamp J.M., et al. Maraviroc, risks and benefits: a review of the clinical literature. Expert Opin. Drug Saf. 7 (2008) 559-569
40. Woodcock J., et al. Pharmacogenetics - tailoring treatment for the outliers. N. Engl. J. Med. 360 (2009) 811-813
41. Kongkaew C., et al. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann. Pharmacother. 42 (2008) 1017-1025
42. Ferrell Jr. P.B., et al. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 9 (2008) 1543-1546
43. Phillips K.A., et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. Am. Med. Assoc. 286 (2001) 2270-2279
44. Jain K.K. Applications of AmpliChip CYP450. Mol. Diagn. 9 (2005) 119-127
45. Dezentje V.O., et al. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res. 15 (2009) 15-21
46. Klein T.E., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360 (2009) 753-764
47. US Food and Drug Administration. FDA approves Updated Warfarin (Coumadin) prescribing Information (2007). http://www.fda.gov/bbs/topics/news/2007/new01684.html (http://www.fda.gov/bbs/topics/news/2007/new01684.html)
48. Proposed Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400N) (2009) (https://www.cms.hhs.gov/scripts/ctredirector.dll/.pdf?@_CPR0a0a043a07d1.ZM_nlMZ_z3MI)
49. Nebert D.W., et al. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev. 40 (2008) 187-224
50. Business Week (2005) Drugs Get Smart (http://www.businessweek.com/magazine/content/05_36/b3949001_mz001.htm)
51. Davis J.C., et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 8 (2009) 279-286